5 minutes	Considerations and Challenges in Second-line Treatment of MF
15 minutes	Review of Approved and Emerging Agents
10 minutes	Audience Q & A

Target Audience
This activity is designed for hematologists, hematologist/oncologists, nurses, advanced practice nurses, and pharmacists who provide care to patients with myelofibrosis.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

• Describe clinical practice considerations for the use of new second-line therapies for the treatment of MF
• Discuss emerging and investigational second-line therapies for the treatment of MF
• Compare available and emerging strategies for managing patients with identified ruxolitinib resistance, failure, and/or loss of response

Disclosure The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. As an organization accredited by the Accreditation Council for Pharmacy Education (ACPE), MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. Faculty Disclosures Dr. Prithviraj Bose has disclosed relevant financial relationships related to advisory activities from AbbVie Inc., Blueprint Medicines, Bristol Myers Squibb Company, Cogent Biosciences, Inc., Constellation Pharmaceuticals, CTI BioPharma Corp., Karyopharm Therapeutics, MorphoSys AG, Novartis AG, PharmaEssentia Corporation, and Sierra Oncology, Inc. He is on the speakers’ bureau for Bristol Myers Squibb, CTI BioPharma, Incyte Corporation, and Sierra Oncology. Dr. Andrew Kuykendall has disclosed relevant financial relationships related to advisory activities from AbbVie Inc., Blueprint Medicines, Celgene Corporation ‒ A Bristol Myers Squibb Company, CTI BioPharma Corp., Imago BioSciences, Incyte Corporation, Novartis AG, and Sierra Oncology, Inc. He is on the speakers’ bureau for Blueprint Medicines, Celgene Corporation ‒ A Bristol Myers Squibb Company, and Incyte, and has received research grant(s) from Blueprint Medicines, Celgene Corporation ‒ A Bristol Myers Squibb Company, and Sierra Oncology. All of the relevant financial relationships listed for these individuals have been mitigated. Unapproved Product Use This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience the discussion of off-label or investigational uses of products or devices.

Planning Committee The following planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. MediCom Worldwide, Inc.: Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager The University of Texas MD Anderson Cancer Center: Tamara Greiner, MA, Associate Director, and Danya Garner, MSN, Associate Director, CPE Peer Reviewer Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients. Instructions for Participation and Credit There are no fees for participating in this activity. A post activity evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. In order to receive credit, all participants must complete the self-assessment post-test and evaluation within 14 days of completing the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit. CME, NCPD, and CE Credit certificates will be emailed 4 weeks following receipt of completed requirements. CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation If you have any questions regarding the content of this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x130 or [email protected].